Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
Oncotelic Therapeutics and Sapu Nano announced a peer-reviewed publication in Biomedicines validating the preclinical translational package for Sapu003, an intravenous formulation of everolimus. The study demonstrates favorable pharmacokinetics, reduced gastrointestinal accumulation compared to oral administration, and successful reproducible cGMP manufacturing of the Deciparticle™ formulation.
Key figures
- Phase Of Trial
- Phase 1b
- Issued patents
- 75
- Clinical Trial Id
- NCT07369505
- Gmp bio ownership
- 45%
- Patent applications
- over 500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.